Waters Corporation (WAT) Stock Price & How to Invest

Waters Corporation, based in Milford, Massachusetts, builds the instruments that regulated laboratories use to find out what is in a sample and how much of it. The core lines are liquid chromatography (the ACQUITY and Alliance iS systems), mass spectrometry (Xevo and SYNAPT), thermal analysis and rheometry under the TA Instruments brand, and Empower, the chromatography data software that most pharmaceutical quality-control labs run their methods on. Legacy end markets skew heavily toward pharma and biopharma at roughly ~58% of sales, with industrial and applied testing near ~31% and academic and government customers around ~11%. The February 2026 combination with BD's Biosciences and Diagnostic Solutions business bolted on flow cytometry and reagents plus clinical microbiology and specimen management, adding roughly ~$3B of annual revenue and pushing Waters into diagnostics for the first time.

The investment case rests on razor-and-blade mechanics. An instrument is sold once; the columns, vials, chemistry kits and multi-year service contracts attached to it are bought for a decade or more, and a validated method in an FDA-regulated lab is expensive to move to a competitor. Consumables and service now clear half of total revenue, and chemistry consumables grew ~10% in the second quarter of 2026. After the 2023 and 2024 instrument downturn, when pharma froze capital budgets and China demand fell away, the replacement cycle has turned: Q2 2026 legacy organic revenue grew ~9% in constant currency and management raised full-year adjusted EPS guidance to ~$14.45 to ~$14.65. Against a ~$40.7B market value, the stock trades near ~28x that number, so the integration and the promised synergy math are doing real work in the price.

Integration risk is the dominant one, because the acquired revenue is close to the size of legacy Waters and diagnostics is a category this management team has not run before. The ~39.2% share issuance diluted existing holders substantially, and the ~$4B of added debt limits flexibility until leverage comes down. Reverse Morris Trust structures also carry tax constraints for a period after closing, which restricts what Waters can do with its own equity in the near term. Underneath the deal sits an unchanged cyclical exposure: pharma capital spending, academic and government research funding, China stimulus and tariffs all move instrument orders around, and Thermo Fisher, Agilent and Danaher's SCIEX compete hard on price and bundled service. At roughly ~28x forward adjusted earnings, a synergy shortfall or a stalled instrument cycle would likely compress the multiple and the earnings estimate together.

23 analysts publish price targets on WAT, averaging $436.00 against a $414.44 price as of August 2026, or +5.2%. The published targets run from $349.00 to $475.00, a narrow spread, and the ratings split 16 buy, 8 hold, 0 sell. Over the last six months there have been 9 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full WAT forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Waters Corporation. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. The BD combination closed, and Waters kept the ticker. The transaction completed on February 9, 2026 as a Reverse Morris Trust: BD spun off its Biosciences and Diagnostic Solutions business to BD shareholders, and that entity merged into Waters. The most optimistic published target, $475.00, assumes this works close to its best case.

The case against. Integration risk is the dominant one, because the acquired revenue is close to the size of legacy Waters and diagnostics is a category this management team has not run before. The most pessimistic target, $349.00, is roughly what WAT is worth if this bites instead.

Read the full bull and bear case on WAT, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Waters Corporation's investor relations page or your broker.

• Revenue (TTM): ~$4.64B
• FY2026 revenue guidance: ~$6.42B to ~$6.48B
• Q2 2026 adjusted EPS: ~$3.05
• FY2026 adjusted EPS guidance: ~$14.45 to ~$14.65
• Market cap: ~$40.7B
• Forward P/E (FY2026 adj. EPS midpoint): ~28x

The trailing revenue figure straddles pre-deal and post-deal quarters, so it materially understates the current run rate; the ~$6.4B full-year guide is the cleaner read on the combined company. Waters reports adjusted EPS that excludes purchase accounting and integration charges, and the gap between adjusted and GAAP earnings will stay wide while the BD amortization runs. Analyst price targets in August 2026 clustered near ~$420, close to where the stock traded, with a wide dispersion from roughly ~$330 to ~$480 that captures how differently analysts handicap the integration.

If you want WAT exposure as part of a larger bundle rather than directly, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.

Other names that sit close to WAT: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get WAT exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (FIW, PHO, PIO), which spreads the position across many companies. Or build it into a focused thematic portfolio, so WAT sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where WAT fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

WAT pairs a genuinely sticky recurring-revenue franchise with a large integration bet, and at roughly ~28x forward adjusted earnings the stock carries little slack if the acquired BD businesses stall.

Whether WAT is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is WAT a buy or a sell?, and where the stock could go from here in the WAT stock forecast.

For income investors, whether WAT pays a dividend and how the payout looks is covered in does WAT pay a dividend? And to weigh WAT against a peer, read the full side-by-side comparisons: WAT vs TMO and WAT vs DHR.